Detection of CSCs by the expression of corresponding markers in other tumors include pancreatic carcinoma (epithelial-specific antigen (ESA), CD24, CD44) [7], medulloblastomas and gliomas (CD133) [13], epithelial ovarian cancers (CD117 (c-kit), CD44) [3], malignant melanoma (ATP-binding cassette sub-family B member 5 (ABCB5)) [8], prostate cancer (CD133, α2β1 integrin, CD44) [4], lung cancer (CD133) [6], among others. This evidence concerns the gene PROM1 and melanoma.